ES2211055T3 - Procedimiento para el tratamiento de enfermedades o trastornos del oido interno. - Google Patents
Procedimiento para el tratamiento de enfermedades o trastornos del oido interno.Info
- Publication number
- ES2211055T3 ES2211055T3 ES99910259T ES99910259T ES2211055T3 ES 2211055 T3 ES2211055 T3 ES 2211055T3 ES 99910259 T ES99910259 T ES 99910259T ES 99910259 T ES99910259 T ES 99910259T ES 2211055 T3 ES2211055 T3 ES 2211055T3
- Authority
- ES
- Spain
- Prior art keywords
- cells
- inner ear
- sensory
- cell
- kip1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 210000003027 ear inner Anatomy 0.000 title claims abstract description 41
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 20
- 201000010099 disease Diseases 0.000 title claims abstract description 9
- 238000000034 method Methods 0.000 title abstract description 15
- 230000001953 sensory effect Effects 0.000 claims abstract description 59
- 102000000577 Cyclin-Dependent Kinase Inhibitor p27 Human genes 0.000 claims abstract description 24
- 108010016777 Cyclin-Dependent Kinase Inhibitor p27 Proteins 0.000 claims abstract description 24
- 230000006378 damage Effects 0.000 claims abstract description 20
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 17
- 208000035475 disorder Diseases 0.000 claims abstract description 7
- 239000013543 active substance Substances 0.000 claims description 26
- 230000008929 regeneration Effects 0.000 claims description 17
- 238000011069 regeneration method Methods 0.000 claims description 17
- 150000007523 nucleic acids Chemical class 0.000 claims description 15
- 108020004707 nucleic acids Proteins 0.000 claims description 14
- 102000039446 nucleic acids Human genes 0.000 claims description 14
- 102000016736 Cyclin Human genes 0.000 claims description 11
- 108050006400 Cyclin Proteins 0.000 claims description 11
- 229940043355 kinase inhibitor Drugs 0.000 claims description 8
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims description 8
- 230000000692 anti-sense effect Effects 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 229940123587 Cell cycle inhibitor Drugs 0.000 abstract description 14
- 210000004209 hair Anatomy 0.000 abstract description 10
- 230000035755 proliferation Effects 0.000 abstract description 6
- 230000008569 process Effects 0.000 abstract description 4
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000002875 cyclin dependent kinase inhibitor Substances 0.000 abstract 1
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 abstract 1
- 230000001172 regenerating effect Effects 0.000 abstract 1
- 230000004936 stimulating effect Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 99
- 108090000623 proteins and genes Proteins 0.000 description 19
- 108090000765 processed proteins & peptides Proteins 0.000 description 16
- 210000002768 hair cell Anatomy 0.000 description 15
- 239000003112 inhibitor Substances 0.000 description 15
- 210000003477 cochlea Anatomy 0.000 description 14
- 102000004169 proteins and genes Human genes 0.000 description 12
- 241000124008 Mammalia Species 0.000 description 11
- 210000000981 epithelium Anatomy 0.000 description 11
- 230000003993 interaction Effects 0.000 description 11
- 230000022131 cell cycle Effects 0.000 description 9
- 230000032823 cell division Effects 0.000 description 9
- 238000011813 knockout mouse model Methods 0.000 description 7
- 210000002985 organ of corti Anatomy 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 239000013603 viral vector Substances 0.000 description 7
- 102000002554 Cyclin A Human genes 0.000 description 6
- 108010068192 Cyclin A Proteins 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 6
- 241000282414 Homo sapiens Species 0.000 description 6
- 239000003184 complementary RNA Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000013598 vector Substances 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 108020005544 Antisense RNA Proteins 0.000 description 5
- 108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 description 5
- 102000015792 Cyclin-Dependent Kinase 2 Human genes 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 125000003275 alpha amino acid group Chemical group 0.000 description 5
- 230000004069 differentiation Effects 0.000 description 5
- 241000271566 Aves Species 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 208000016354 hearing loss disease Diseases 0.000 description 4
- 230000011278 mitosis Effects 0.000 description 4
- 230000001338 necrotic effect Effects 0.000 description 4
- 206010011878 Deafness Diseases 0.000 description 3
- 108091000080 Phosphotransferase Proteins 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 231100000895 deafness Toxicity 0.000 description 3
- 230000008030 elimination Effects 0.000 description 3
- 238000003379 elimination reaction Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 102000020233 phosphotransferase Human genes 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 108020004491 Antisense DNA Proteins 0.000 description 2
- 102000003903 Cyclin-dependent kinases Human genes 0.000 description 2
- 108090000266 Cyclin-dependent kinases Proteins 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 101000944364 Mus musculus Cyclin-dependent kinase inhibitor 1B Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 description 2
- 229960004821 amikacin Drugs 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000003816 antisense DNA Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 210000000243 deiters cell Anatomy 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000007431 microscopic evaluation Methods 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 108020004394 Complementary RNA Proteins 0.000 description 1
- 101001090813 Homo sapiens Proteasome subunit alpha type-6 Proteins 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 101100460719 Mus musculus Noto gene Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 102100034664 Proteasome subunit alpha type-6 Human genes 0.000 description 1
- 208000031439 Striae Distensae Diseases 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 210000000721 basilar membrane Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 210000000959 ear middle Anatomy 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000009395 genetic defect Effects 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- -1 lipid compounds Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000001044 sensory neuron Anatomy 0.000 description 1
- 210000000697 sensory organ Anatomy 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000001720 vestibular Effects 0.000 description 1
- 210000000605 viral structure Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19807426A DE19807426A1 (de) | 1998-02-23 | 1998-02-23 | Verfahren zur Behandlung von Erkrankungen oder Störungen des Innenohrs |
| DE19807426 | 1998-02-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2211055T3 true ES2211055T3 (es) | 2004-07-01 |
Family
ID=7858563
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES99910259T Expired - Lifetime ES2211055T3 (es) | 1998-02-23 | 1999-02-23 | Procedimiento para el tratamiento de enfermedades o trastornos del oido interno. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US7087581B1 (enExample) |
| EP (1) | EP1056467B1 (enExample) |
| JP (1) | JP2002503687A (enExample) |
| AT (1) | ATE250936T1 (enExample) |
| AU (1) | AU763868B2 (enExample) |
| CA (1) | CA2320717C (enExample) |
| DE (2) | DE19807426A1 (enExample) |
| DK (1) | DK1056467T3 (enExample) |
| ES (1) | ES2211055T3 (enExample) |
| PT (1) | PT1056467E (enExample) |
| WO (1) | WO1999042088A2 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2325198A1 (en) | 1999-06-01 | 2011-05-25 | Baylor College Of Medicine | Compositions and methods for the therapeutic use of an atonal-associated sequence |
| DE10027777A1 (de) * | 2000-06-07 | 2001-12-13 | Otogene Ag | Transfektionsverfahren |
| CA2412764C (en) * | 2000-07-11 | 2014-06-03 | Sound Pharmaceuticals Incorporated | Stimulation of cellular regeneration and differentiation in the inner ear |
| JP4533144B2 (ja) | 2002-10-02 | 2010-09-01 | アンジェスＭｇ株式会社 | 聴覚機能障害用医薬 |
| EP1585523B1 (en) * | 2002-12-17 | 2008-10-01 | Centre National De La Recherche Scientifique (Cnrs) | Use of purine derivatives for inducing differentiation of supernumerary hair cells and deiters' cells in the developing organ of corti for treating deafness |
| EP2293800B1 (en) | 2008-06-06 | 2016-10-05 | Quark Pharmaceuticals, Inc. | Compositions and methods for treatment of ear disorders |
| DE102010007281A1 (de) * | 2010-02-08 | 2011-08-11 | EMC microcollections GmbH, 72070 | Neue Aminoalkyl-oxazol- und Aminoalkyl-thiazolcarbonsäureamide und ihre Anwendung zur Stimulation der endogenen situ Regeneration von Haarsinneszellen im Corti'schen Organ des Innenohres beim Säuger |
| RU2480195C1 (ru) * | 2011-11-02 | 2013-04-27 | Федеральное государственное учреждение "Российский научный центр восстановительной медицины и курортологии Федерального агентства по здравоохранению и социальному развитию РФ" (ФГУ "РНЦВМиК Росздрава РФ") | Способ лечения заболеваний внутреннего уха |
| EP2802657B1 (en) | 2012-01-12 | 2018-05-02 | Quark Pharmaceuticals, Inc. | Combination therapy for treating hearing and balance disorders |
| WO2013134022A1 (en) * | 2012-03-05 | 2013-09-12 | Wake Forest University Health Sciences | Regeneration of inner ear cells |
| TWI710635B (zh) | 2014-10-09 | 2020-11-21 | 美商珍維克公司 | 編碼人類無調同源物-1(hath1)之腺病毒載體 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19528388A1 (de) * | 1995-08-02 | 1997-02-06 | Hans Peter Prof Dr Med Zenner | Verwendung von Adamantan-Derivaten zur Behandlung von Erkrankungen des Innenohrs |
| EP0866716A4 (en) | 1995-11-13 | 2002-05-02 | Cambridge Neuroscience Inc | METHOD FOR TREATING DISORDERS OF THE NON-VISUAL SENSORIC EPITHEL |
| US5962224A (en) * | 1995-12-19 | 1999-10-05 | Dana-Farber Cancer Institute | Isolated DNA encoding p62 polypeptides and uses therefor |
| AU3591597A (en) | 1996-06-28 | 1998-01-21 | Regents Of The University Of California, The | Transformation and genetherapy of cells of the inner ear |
| AU4600297A (en) | 1996-09-27 | 1998-04-17 | Trustees Of The University Of Pennsylvania, The | Novel methods for inducing proliferation in auditory receptor epithelium |
| US6043221A (en) * | 1997-07-30 | 2000-03-28 | Amgen Inc. | Method for preventing and treating hearing loss using a neuturin protein product |
-
1998
- 1998-02-23 DE DE19807426A patent/DE19807426A1/de not_active Withdrawn
-
1999
- 1999-02-23 DE DE59907195T patent/DE59907195D1/de not_active Expired - Fee Related
- 1999-02-23 PT PT99910259T patent/PT1056467E/pt unknown
- 1999-02-23 WO PCT/EP1999/001153 patent/WO1999042088A2/de not_active Ceased
- 1999-02-23 DK DK99910259T patent/DK1056467T3/da active
- 1999-02-23 CA CA002320717A patent/CA2320717C/en not_active Expired - Fee Related
- 1999-02-23 ES ES99910259T patent/ES2211055T3/es not_active Expired - Lifetime
- 1999-02-23 EP EP99910259A patent/EP1056467B1/de not_active Expired - Lifetime
- 1999-02-23 US US09/622,719 patent/US7087581B1/en not_active Expired - Lifetime
- 1999-02-23 AU AU29281/99A patent/AU763868B2/en not_active Ceased
- 1999-02-23 AT AT99910259T patent/ATE250936T1/de not_active IP Right Cessation
- 1999-02-23 JP JP2000532105A patent/JP2002503687A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO1999042088A3 (de) | 2000-03-02 |
| EP1056467A2 (de) | 2000-12-06 |
| CA2320717C (en) | 2009-03-24 |
| WO1999042088A2 (de) | 1999-08-26 |
| DE59907195D1 (de) | 2003-11-06 |
| AU2928199A (en) | 1999-09-06 |
| ATE250936T1 (de) | 2003-10-15 |
| PT1056467E (pt) | 2004-02-27 |
| DE19807426A1 (de) | 1999-10-14 |
| CA2320717A1 (en) | 1999-08-26 |
| US7087581B1 (en) | 2006-08-08 |
| AU763868B2 (en) | 2003-07-31 |
| JP2002503687A (ja) | 2002-02-05 |
| EP1056467B1 (de) | 2003-10-01 |
| DK1056467T3 (da) | 2004-02-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2211055T3 (es) | Procedimiento para el tratamiento de enfermedades o trastornos del oido interno. | |
| Reed et al. | Mast cell tryptase and proteinase‐activated receptor 2 induce hyperexcitability of guinea‐pig submucosal neurons | |
| ES2696598T3 (es) | Compuestos de balanol para su uso en el tratamiento de dolor | |
| ES2373540T3 (es) | Entrenamiento cognitivo aumentado. | |
| Hu et al. | The cardioprotective effects of nitroglycerin-induced preconditioning are mediated by calcitonin gene-related peptide | |
| Hannan et al. | Caspase-3 dependent nitrergic neuronal apoptosis following cavernous nerve injury is mediated via RhoA and ROCK activation in major pelvic ganglion | |
| Muthusamy et al. | Complementary roles of the neuron‐enriched endosomal proteins NEEP21 and calcyon in neuronal vesicle trafficking | |
| JP2015042667A (ja) | 認知および運動のリハビリテーションのためのホスホジエステラーゼ４インヒビター | |
| Shizuki et al. | Expression of c-Fos after noise-induced temporary threshold shift in the guinea pig cochlea | |
| ES2403333T3 (es) | Entrenamiento cognitivo aumentado | |
| Park et al. | Intracavernosal injection of vascular endothelial growth factor improves erectile function in aged rats | |
| Iwai et al. | Neuromedin U inhibits inflammation-mediated memory impairment and neuronal cell-death in rodents | |
| Zhang et al. | Neuroregulative mechanism of hypothalamic paraventricular nucleus on gastric ischemia–reperfusion injury in rats | |
| Garthwaite et al. | Soluble guanylyl cyclase activator YC-1 protects white matter axons from nitric oxide toxicity and metabolic stress, probably through Na+ channel inhibition | |
| Phani et al. | Gremlin is a novel VTA derived neuroprotective factor for dopamine neurons | |
| US20080275034A1 (en) | Use of a Phenothiazine Derivative for Preventing and/or Treating Hearing Loss | |
| ES2879375T3 (es) | Procedimientos de manejo del miedo condicionado con antagonistas del receptor de neuroquinina | |
| ES2272050T3 (es) | Nueva familia de canales de potasio de mamiferos mecanosensibles activados por los acidos grasos poliinsaturados y su utilizacion especialmente para el cribado de farmacos. | |
| Erdos et al. | Mechanisms of pain-induced local cerebral blood flow changes in the rat sensory cortex and thalamus | |
| Gil-Loyzaga et al. | Trimetazidine prevents cochlear lesions induced by intraperitoneal and perilymphatic administration of kainic acid | |
| ES2322881B1 (es) | Uso de compuestos agonistas de la actividad pi3k en la elaboracion de composiciones farmaceuticas, dichas composiciones farmaceuticas y sus aplicaciones en el tratamiento de enfermedades neurodegenerativas. | |
| Gozes | Davunetide (NAP) pharmacology: neuroprotection and tau | |
| Tian | POMC/MC4R Signaling in Alzheimer’s Disease | |
| Nair | Kainate Receptor Editing and Plasticity of AMPARs | |
| KR101634440B1 (ko) | AMPA 수용체 GluA1의 인산화 억제제를 포함하는 정신질환의 예방 또는 치료용 약학조성물 |